Fulgent Genetics, Inc. (FLGT)

21,27 -0,05 (-0,23%) Al cierre: 04:00PM EDT

Fulgent Genetics, Inc.

4399 Santa Anita Avenue
El Monte, CA 91731
United States
626 350 0537
https://www.fulgentgenetics.com

Sector(es): Healthcare
Sector: Diagnostics & Research
Empleados a tiempo completo: 1184

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Ming Hsieh	Chairman & CEO	2,31M	N/A	1956
Mr. Jian Xie	COO & President	868,74k	N/A	1966
Mr. Paul Kim	Chief Financial Officer	879,61k	N/A	1967
Dr. Hanlin Gao D.A.B.M.G., FACMG, M.D., Ph.D.	Chief Scientific Officer & Laboratory Director	720,7k	N/A	1967
Ms. Natalie Prescott	General Counsel & Chief Privacy Officer	N/A	N/A	N/A
Ms. Doreen Ng	VP of Operations & Compliance and GM of Houston Office	N/A	N/A	N/A
Mr. Jakub Sram	Vice President of Business Development & Sales	N/A	N/A	N/A
Ms. Ellen Tsui	Vice President of Human Resources	N/A	N/A	N/A
Mr. Brandon Perthuis	Chief Commercial Officer	N/A	N/A	N/A
Dr. Lawrence M. Weiss M.D.	Chief Medical Officer	N/A	N/A	1957

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.

Gobierno corporativo

El ISS Governance QualityScore de Fulgent Genetics, Inc., a día 1 de mayo de 2024, es 5. Las puntuaciones base son Auditoría: 4; Tablero: 7; Derechos de los accionistas: 4; Compensación: 7.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.